# Provider Insights on Managing Patients on Immunotherapy, Barriers to Clinical Trials, and Biomarker Testing Preferences

Tariqa Ackbarali, PhD¹; Joel Neal, MD²; Yelena Janjigian, MD³; and Michael Overman, MD⁴ <sup>1</sup>PlatformQ Health, Needham, MA; <sup>2</sup>Stanford Cancer Institute, Stanford, CA; <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY; <sup>4</sup>MD Anderson Cancer Center, Houston, TX

This activity is supported by educational grants from Genentech; Merck & Co., Inc.; and Regeneron.



Clinical efficacy of first-line

pembrolizumab in stage III

NSCLC: KEYNOTE-799







### INTRODUCTION

With the advent of immunotherapies for a plethora of solid tumors, the standard of care has dramatically shifted. Approved and investigational options shaping the treatment paradigm for cancer include immune checkpoint inhibitors (ICIs), antibody-drug conjugates, CAR-T cell therapies,



and treatments with tumor-infiltrating lymphocytes. The immunotherapy landscape continues to morph and evolve as data from numerous clinical trials are reported, new indications are approved, and emerging combinations with checkpoint inhibitors continue to show promise.

### METHODOLOGY

## **Educational Program and Evaluation Details**



Advocacy group: Society for Immunotherapy of Cancer (SITC)

Education: PlatformQ Health, Postgraduate Institute for Medicine (PIM)




Changes in knowledge, competence, reported behavior, and engagement.


### **Faculty**



**Ensign Professor of Medicine Professor of Pharmacology** Chief of Medical Oncology **Associate Cancer Center Director for** Translational Research Yale Comprehensive Cancer Center **Yale School of Medicine** New Haven, CT



Joel W. Neal, MD, PhD Associate Professor of Medicine/Oncology **Stanford University** 



cancer (CRC).

Yelena Y. Janjigian, MD Associate Professor, WCMC Chief, Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center

Measurements

Interventions

A 2-part educational series was broadcast

live-online in January 2022 and remains

OMedLive.com. The first session focused

on emerging approaches in small cell lung

highlighted updates in gastroesophageal

Questions asked pre and immediately post

learners to evaluate changes in practice. Chi

Square tests were used for statistical analysis.


activity. 2-month follow-up survey was sent to

on-demand through January 2023 at


cancer (SCLC) and non-small cell lung

cancer (NSCLC). The second session

junction cancer (GEJ) and colorectal



Michael Overman, MD Professor, Gastrointestinal Medical Oncology MD Anderson Cancer Center



Session components included downloadable resources and real-time audience Q&A.

# PROGRAM METRICS

#### **Learner Demographics**



target audience

895 certificates

**Learner Engagement** 

# Learner Demographics (Continued)



average weekly visits of lung cancer patients



average weekly visits of lung cancer patients on immunotherapy




average weekly visits of CRC patients on immunotherapy



average weekly visits of gastric cancer or **GEJ** patients on immunotherapy

\*Target Audience: Medical, surgical, and radiation oncologists, gastroenterologists, dermatologists, pulmonologists, primary care physicians, internal medicine specialists, oncology pharmacists, oncology advanced practice nurses and physician assistants, social workers, and other HCPs who participate in the care of patients receiving immunotherapies.

### RESULTS: IMPACT



of learners reported the activity positively impacted their clinical practice





of learners reported the activity positively impacted patient experiences or outcomes

I emphasize to my patients the importance of personalizing immunotherapy.

I follow guidelines and educate patients about side effects and self-care tips.

I provide less toxic, more efficacious treatment for patients.


were shared


I have seen a reduction of treatment-related adverse events.


### RESULTS: CHANGES IN KNOWLEDGE/COMPETENCE AND PROVIDER INSIGHTS

#### Significant improvements were observed across all nine assessment questions.




















### Frequency of Biomarker Test Utilization to **Drive Treatment Planning for Patients**




Approved monotherapies for the first-line treatment











Clinical application of


practice: EMPOWER-1


trial results






Awareness of TRAEs with nivo/ipi vs nivo/chemo: CheckMate 648
















The educational series was successful in improving knowledge and competence immediately after the sessions. Provider practice patterns and perceptions of challenges













Patient discussions of


first-line immunotherapy

for dMMR/MSI-H mCRC

29%

**77**%

increase





Patient interest

CONCLUSION

were insightful regarding further educational opportunities for providers, as well as patients.